Spots Global Cancer Trial Database for A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Official Title: Phase 1b/2 Study of LY3200882 and Pembrolizumab in Patients With Advanced Cancer
Study ID: NCT04158700
Conditions
Study Description
Brief Summary: The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dana Farber Cancer Institute, Boston, Massachusetts, United States
CHU de Besancon Hopital Jean Minjoz, Besancon Cedex, , France
Gustave Roussy, Villejuif Cedex, , France
Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Clinic I Provincial, Barcelona, , Spain
Hospital Madrid Norte Sanchinarro, Madrid, , Spain
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
